Efficacy and Safety of Topical Travoprost with Sofzia(R) Preservative for Japanese Glaucoma Patients

Kanamoto Takashi

Kiuchi Yoshiaki

Suehiro Tatsunori

Nakano Tohru

Nakano Yutaka

Hirota Atsushi

Miyata Akira

Hiroshima Journal of Medical Sciences

[PISSN] 0018-2052

[EISSN] 2433-7668

[NCID] AA00664312

The purpose of this study is to evaluate the intraocular pressure (IOP) -lowering effect and safety of topical travoprost with sofziaR and without benzalkonium chloride on Japanese patients with glaucoma. Topical travoprost (0.04%) was used on 39 glaucoma patients with no prior use of topical prostaglandin F2a analogues (Beginning group). The IOP, number of conjunctiva! follicules, degrees of conjunctiva! hyperemia, and degrees of superficial punctate keratitis (SPK, AD-classification) were determined at the beginning of the treatment and after 1 month and 3 months. 37 other patients who were using 0.005% topical latanoprost were switched to 0.04% topical travoprost and analyzed in the same way (Switched group). For the Beginning group, the IOP was significantly decreased after 3 months (p <0.0001). The conjunctiva! follicule score was decreased significantly (p =0.033). Both the SPK area score and density score for the cases with SPK at the baseline decreased significantly (p =0.034 and p =0.024). In the switched group, the IOP was not changed significantly at 3 months after the switch (p =0.118). Both the conjunctiva! follicule and hyperemia score were significantly decreased at 3 month (p =0.0074 and p =0.0047). The SPK area score for the cases with SPK at the time of switch decreased significantly (p =0.013). Travoprost with sofziaR preservative had an equal effect in reducing the IOP as latanoprost. It had low toxicity on the ocular surface of Japanese glaucoma patients.

Travoprost

Glaucoma

Intraocular pressure

Safety

SofziaR

Medical sciences [ 490 ]

eng

Hiroshima University Medical Press

(c) Hiroshima University Medical Press.

[ISSN] 0018-2052

[NCID] AA00664312